Kim A. Connelly


Scientist, Keenan Research Centre for Biomedical Science


Dr. Kim Connelly is a Cardiologist and Scientist who is both nationally recognized as an expert in human and rodent echocardiography, cardiovascular MRI and the impact of diabetes upon cardiac function. His work has been recognized evident by winning the “Young Investigator of the Year Award” in 2012 by the Canadian Cardiovascular Society an Early Researcher Award in 2014, and a Canadian Institutes of Health Research (CIHR) New Investigator award in 2014.

Dr. Connelly runs a basic research laboratory at the Keenan Research Centre for Biomedical Science (KRCBS) at St. Michael’s Hospital where he focuses upon basic mechanisms of disease – primarily around the role of pathological extracellular matrix accumulation and the pro-sclerotic cytokine transforming growth factor beta, with a focus upon translating discoveries into therapies in humans. He is the Director of the Krembil Stem Cell Facility at St. Michael’s Hospital and uses stem cell based therapies to improve cardiac and renal dysfunction as a result of diabetes. He collaborates extensively not only locally in Toronto but also nationally and internationally – with research support from the Heart and Stroke Foundation (HSF) of Canada, CIHR and Canadian Foundation for Innovation along with significant research support from the pharmaceutical industry.

Locally, he sits on the executive of the University of Toronto Cardiovascular research network, and has been a reviewer for both the CIHR “CSB” panel, along with the Heart and Stroke Foundation of Canada (HSF). He was the national spokesperson for the HSF of Canada “heart healthy month” in February 2015.

Recent Publications

  1. Bami, K, Gandhi, S, Leong-Poi, H, Yan, AT, Ho, E, Zahrani, M et al.. Effects of Empagliflozin on Left Ventricular Remodeling in Patients with Type 2 Diabetes and Coronary Artery Disease: Echocardiographic Substudy of the EMPA-HEART CardioLink-6 Randomized Clinical Trial. J Am Soc Echocardiogr. 2020; :. doi: 10.1016/j.echo.2020.02.005. PubMed PMID:32199780 .
  2. Singh, S, Adam, M, Matkar, PN, Bugyei-Twum, A, Desjardins, JF, Chen, HH et al.. Endothelial-specific Loss of IFT88 Promotes Endothelial-to-Mesenchymal Transition and Exacerbates Bleomycin-induced Pulmonary Fibrosis. Sci Rep. 2020;10 (1):4466. doi: 10.1038/s41598-020-61292-9. PubMed PMID:32161282 PubMed Central PMC7066128.
  3. Opingari, E, Verma, S, Connelly, KA, Mazer, CD, Teoh, H, Quan, A et al.. The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 trial. Nephrol. Dial. Transplant. 2020; :. doi: 10.1093/ndt/gfz294. PubMed PMID:32159783 .
  4. Abrahamson, JR, Read, A, Chin, K, Mistry, N, Joo, H, Desjardins, JF et al.. Renal Tissue PO2 Sensing During Acute Hemodilution is Dependent on the Diluent. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2020; :. doi: 10.1152/ajpregu.00323.2019. PubMed PMID:32130021 .
  5. Connelly, KA, Zhang, Y, Desjardins, JF, Nghiem, L, Visram, A, Batchu, SN et al.. Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction. Cardiovasc Diabetol. 2020;19 (1):13. doi: 10.1186/s12933-020-0994-y. PubMed PMID:32035482 PubMed Central PMC7007658.
  6. Chowdhury, B, Luu, AZ, Luu, VZ, Kabir, MG, Pan, Y, Teoh, H et al.. The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension. Biochem. Biophys. Res. Commun. 2020;524 (1):50-56. doi: 10.1016/j.bbrc.2020.01.015. PubMed PMID:31980166 .
  7. Taramasso, M, Gavazzoni, M, Pozzoli, A, Alessandrini, H, Latib, A, Attinger-Toller, A et al.. Outcomes of TTVI in Patients With Pacemaker or Defibrillator Leads: Data From the TriValve Registry. JACC Cardiovasc Interv. 2020;13 (5):554-564. doi: 10.1016/j.jcin.2019.10.058. PubMed PMID:31954676 .
  8. Paterson, DI, Wells, G, Erthal, F, Mielniczuk, L, O'Meara, E, White, J et al.. OUTSMART HF: A Randomized Controlled Trial of Routine Versus Selective Cardiac Magnetic Resonance for Patients With Nonischemic Heart Failure (IMAGE-HF 1B). Circulation. 2020;141 (10):818-827. doi: 10.1161/CIRCULATIONAHA.119.043964. PubMed PMID:31910649 .
  9. Altaha, MA, Nolan, M, Marwick, TH, Somerset, E, Houbois, C, Amir, E et al.. Can Quantitative CMR Tissue Characterization Adequately Identify Cardiotoxicity During Chemotherapy?: Impact of Temporal and Observer Variability. JACC Cardiovasc Imaging. 2019; :. doi: 10.1016/j.jcmg.2019.10.016. PubMed PMID:31864977 .
  10. Fam, NP, Braun, D, von Bardeleben, RS, Nabauer, M, Ruf, T, Connelly, KA et al.. Compassionate Use of the PASCAL Transcatheter Valve Repair System for Severe Tricuspid Regurgitation: A Multicenter, Observational, First-in-Human Experience. JACC Cardiovasc Interv. 2019;12 (24):2488-2495. doi: 10.1016/j.jcin.2019.09.046. PubMed PMID:31857018 .
Search PubMed

Affiliations & Other Activities

  • Director, Krembil Stem Cell Facility, St. Michael’s Hospital
  • Staff Cardiologist, Division of Cardiology, St. Michael’s Hospital
  • Member, Richard Lewar Center, University of Toronto
  • Cardiologist, Division of Cardiology, Sunnybrook Health Sciences Centre